PRE

Prenetics Global Limited Class A Ordinary Share (PRE) | Rumor.io

Prenetics Global

PRE

Attention (50-day avg)0%

Attention rank (50-day avg)#4,057

Bullish sentiment (50-day avg)100%

Price to earnings ratio1.06

Market capitalization381.9M

Earnings per share-3.46

Dividend yield (TTM)—

Revenue (annual)92.4M

Net income (annual)-40M

Social

What share of all stock conversation is about PRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jun 18

Prenetics Global Limited (PRE) has received FDA clearance for its ACTOnco genomic profiling test, leading to an 8.5% gain in pre-market trading.
The company is expected to break out from a triangle pattern, with a potential target price of $10.00 and a stop loss at $7.00.
Prenetics Global has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings to Delta Electronics for up to $71.78M, bolstering the company's financial position and increasing its pro-forma cash reserves to approximately $86M.

Generated by AI

Sentiment

Of the messages about PRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	97.75% +5.75
Bearish	—	—	0%	2.25% -5.75

Bullish· Jan 12

The company has a strong fundamental profile, with positive revenue already coming in and a significant amount of cash on hand, setting it up for a potentially positive Q4 earnings report.
The stock has a high price target of over $11.00, with some analysts predicting it will reach this level due to its accumulation zone.
The company has a share repurchase program in place, authorizing the purchase of up to $20 million worth of its own shares, which could help to boost the stock's price.

Bearish· Jan 11

Prenetics Global Limited's stock price has dropped ~19% following FDA approval for its genomic profiling test.
The company's stock price has fallen below its pre-news level, with some investors labeling it a "joke".
There are concerns about Prenetics Global Limited's financial health, including allegations of being a "Chinese Scam SPAC" with no profit until 2026 and declining Covid test revenue.

Generated by AI

Topics

Of the messages about PRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	69.32%
Analysts	—	—	—	3.41%
Controversies	—	—	—	0%
Earnings	—	—	—	1.42%
Macro	—	—	—	1.42%
Technical Analysis	—	—	—	24.43%

Announcements· Jan 10

Prenetics' subsidiary ACT Genomics received FDA clearance for its comprehensive genomic profiling test, ACTOnco, for all solid tumors, making it the first Asia-based company to receive such clearance.
Prenetics' stock surged by 74.7% in premarket trading following the FDA clearance news, with some investors expecting further gains.
The FDA clearance is a significant milestone for Prenetics, a Hong Kong-based company with over 600 employees, and may lead to increased revenue and EBITDA guidance for the company.

Technical Analysis· Jan 10

$PRE has been in a downtrend, with a break above $3.50 needed for potential entries.
The stock has key support at $2.40 and a trend line at $2.50 that needs to be broken for a reversal.
$PRE has been a solid short since failing to break above $3.20, with a potential run expected if it breaks above $3.15.

Generated by AI

Community

Of the messages about PRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.12%	88.89%	80%	25.06%
Newcomers	5.88%	11.11%	20%	74.94%

Regulars· Jan 10

Prenetics' (PRE) owned ACT Genomics receives FDA clearance for ACTOnco, a comprehensive genomic profiling test for all solid tumors, marking the first Asia-based company to achieve this clearance.
The FDA clearance for ACTOnco is expected to positively impact Prenetics' business, as it expands the company's offerings and increases its competitiveness in the market.
Prenetics Global Limited Class A Ordinary Share (PRE) experiences a significant price increase, up 34% since the previous day's close, with high relative volume, indicating a potential surge in trading activity.

Newcomers· Jan 11

The newcomer is excited about Prenetics Global Limited ($PRE) due to recent FDA news, which they believe could lead to a significant price increase.
The newcomer is reflecting on a recent trading experience with $PRE, realizing they held onto the stock for too long after a bounce, resulting in a loss of $75.21.
The newcomer is attempting to refine their trading strategy for $PRE by reverse-engineering a successful trade, aiming to become more systematic and improve their execution.

Generated by AI

Prenetics Global (NASDAQ:PRE) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by

9d agoBenzinga

B.Riley initiates Prenetics stock coverage with buy rating on IM8 growth

1mo agoInvesting.com

Prenetics Global Insider Bought Shares Worth $497,700, According to a Recent SEC Filing

Brian J Rosin, Chief Financial Officer of IM8 (US) LLC, on August 24, 2026, executed a purchase for

1mo agofinance.yahoo.com

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Detailed price information for Prenetics Global Limited Class A Ordinary Share (PRE-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Prenetics: Marketing Mastery The Key To Robust Revenue Growth (NASDAQ:PRE)

Prenetics (PRE) stock analysis: IM8 growth to 140k subs, AI-driven marketing, and General Catalyst CAC financing.

1mo agoSeeking Alpha

Prenetics Global Ltd (PRE) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

1mo agoYahoo Finance

Also Discussed

Investors talking about PRE also mention

#	Name	Attention
1	Grupo Cibest S.A. ADRCIB	0%0
2	Clean Harbors, Inc.CLH	0%0
3	Affiliated Managers Group, Inc.AMG	0%new
4	Ecopetrol S.A. Sponsored ADREC	0%0
5	MultiMetaVerse Holdings LimitedMMV	0%new
6	The Brink's CompanyBCO	0%0
7	Scharf ETFKAT	0%new
8	Grupo Aval Acciones y Valores SAAVAL	0%0
9	Copa Holdings, S.A. Class A Common StockCPA	0%new
10	iShares MSCI Global Gold Miners ETFRING	0%0

Prenetics Global Limited Class A Ordinary Share

Consumer Defensive
Packaged Foods

Prenetics Global Limited Class A Ordinary Share is the common equity security of Prenetics Global Limited, a health sciences company focused on consumer health products and services. The company operates through brands and platforms that include IM8, which offers scientifically formulated supplements and longevity-focused nutrition products, Europa, which provides sports nutrition products, and CircleDNA, a direct-to-consumer DNA testing service. Prenetics Global Limited serves consumers seeking wellness, nutrition, and genetic insights, with its products distributed across multiple markets in the United States, Hong Kong, and other international regions. The Class A Ordinary Share represents an ownership interest in the company’s current health and wellness business segments and reflects its role in the broader consumer health sciences market.

Website

Location

Unit 703-706, K11 Atelier King’s Road

Quarry Bay

Hong Kong

Social

What share of all stock conversation is about PRE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jun 18

Prenetics Global Limited (PRE) has received FDA clearance for its ACTOnco genomic profiling test, leading to an 8.5% gain in pre-market trading.
The company is expected to break out from a triangle pattern, with a potential target price of $10.00 and a stop loss at $7.00.
Prenetics Global has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings to Delta Electronics for up to $71.78M, bolstering the company's financial position and increasing its pro-forma cash reserves to approximately $86M.

Generated by AI

Sentiment

Of the messages about PRE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	97.75% +5.75
Bearish	—	—	0%	2.25% -5.75

Bullish· Jan 12

The company has a strong fundamental profile, with positive revenue already coming in and a significant amount of cash on hand, setting it up for a potentially positive Q4 earnings report.
The stock has a high price target of over $11.00, with some analysts predicting it will reach this level due to its accumulation zone.
The company has a share repurchase program in place, authorizing the purchase of up to $20 million worth of its own shares, which could help to boost the stock's price.

Bearish· Jan 11

Prenetics Global Limited's stock price has dropped ~19% following FDA approval for its genomic profiling test.
The company's stock price has fallen below its pre-news level, with some investors labeling it a "joke".
There are concerns about Prenetics Global Limited's financial health, including allegations of being a "Chinese Scam SPAC" with no profit until 2026 and declining Covid test revenue.

Generated by AI

Topics

Of the messages about PRE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	69.32%
Analysts	—	—	—	3.41%
Controversies	—	—	—	0%
Earnings	—	—	—	1.42%
Macro	—	—	—	1.42%
Technical Analysis	—	—	—	24.43%

Announcements· Jan 10

Prenetics' subsidiary ACT Genomics received FDA clearance for its comprehensive genomic profiling test, ACTOnco, for all solid tumors, making it the first Asia-based company to receive such clearance.
Prenetics' stock surged by 74.7% in premarket trading following the FDA clearance news, with some investors expecting further gains.
The FDA clearance is a significant milestone for Prenetics, a Hong Kong-based company with over 600 employees, and may lead to increased revenue and EBITDA guidance for the company.

Technical Analysis· Jan 10

$PRE has been in a downtrend, with a break above $3.50 needed for potential entries.
The stock has key support at $2.40 and a trend line at $2.50 that needs to be broken for a reversal.
$PRE has been a solid short since failing to break above $3.20, with a potential run expected if it breaks above $3.15.

Generated by AI

Community

Of the messages about PRE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	94.12%	88.89%	80%	25.06%
Newcomers	5.88%	11.11%	20%	74.94%

Regulars· Jan 10

Prenetics' (PRE) owned ACT Genomics receives FDA clearance for ACTOnco, a comprehensive genomic profiling test for all solid tumors, marking the first Asia-based company to achieve this clearance.
The FDA clearance for ACTOnco is expected to positively impact Prenetics' business, as it expands the company's offerings and increases its competitiveness in the market.
Prenetics Global Limited Class A Ordinary Share (PRE) experiences a significant price increase, up 34% since the previous day's close, with high relative volume, indicating a potential surge in trading activity.

Newcomers· Jan 11

The newcomer is excited about Prenetics Global Limited ($PRE) due to recent FDA news, which they believe could lead to a significant price increase.
The newcomer is reflecting on a recent trading experience with $PRE, realizing they held onto the stock for too long after a bounce, resulting in a loss of $75.21.
The newcomer is attempting to refine their trading strategy for $PRE by reverse-engineering a successful trade, aiming to become more systematic and improve their execution.

Generated by AI

Prenetics Global

Social

Jun 18

Bullish· Jan 12

Bearish· Jan 11

Announcements· Jan 10

Technical Analysis· Jan 10

Regulars· Jan 10

Newcomers· Jan 11

Prenetics Global Q2 2026 Earnings Call: Complete Transcript - Prenetics Global (NASDAQ:PRE)

B.Riley initiates Prenetics stock coverage with buy rating on IM8 growth

Prenetics Global Insider Bought Shares Worth $497,700, According to a Recent SEC Filing

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics: Marketing Mastery The Key To Robust Revenue Growth (NASDAQ:PRE)

Prenetics Global Ltd (PRE) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

Also Discussed

Prenetics Global Limited Class A Ordinary Share

Company Information

Location

Prenetics Global Q2 2026 Earnings Call: Complete Transcript - Prenetics Global (NASDAQ:PRE)

B.Riley initiates Prenetics stock coverage with buy rating on IM8 growth

Prenetics Global Insider Bought Shares Worth $497,700, According to a Recent SEC Filing

Prenetics (PRE) Q2 2026 Earnings Call Transcript

Prenetics: Marketing Mastery The Key To Robust Revenue Growth (NASDAQ:PRE)

Prenetics Global Ltd (PRE) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

Also Discussed

Social

Jun 18

Bullish· Jan 12

Bearish· Jan 11

Announcements· Jan 10

Technical Analysis· Jan 10

Regulars· Jan 10

Newcomers· Jan 11